Former Chief Medical Officer · Rapport Therapeutics, Inc. (RAPP)

Bradley Galer

FY2024 is the first fiscal year CompBrief holds for Bradley Galer as a named executive officer of Rapport Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,431,474

Salary $466,885Stock awards $0Bonus $75,000

3rd of 3 named executive officers at Rapport Therapeutics by FY2024 total.

3 named officers on file for Rapport Therapeutics, FY2024

Bradley Galer’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Rapport Therapeutics’s whole pay program stands against its peers

  • Rapport Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RAPP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A).

Free

Get Bradley Galer’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Bradley Galer compensation by year

Rapport Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Rapport Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$466,885
Bonus$75,000
Stock awards$0
Option awards$1,707,981
Non-equity incentive$163,200
Pension and deferred compensation$0
All other$18,408
Total$2,431,474

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Rapport Therapeutics, Inc. DEF 14A filed April 24, 2025, accession 0001193125-25-092133, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Rapport Therapeutics, Inc. filed document, accession 0001193125-25-092133. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU53,750$953,525—
RSU48,710$864,115—
Option50,615—$1.80
Option17,513—$9.60
Option123,818—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Rapport Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Rapport Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Abraham CeesayChief Executive Officer$9,839,157
Troy IgnelziChief Financial Officer$2,464,371
Bradley Galer · this pageFormer Chief Medical Officer$2,431,474

The full Rapport Therapeutics compensation record

free company brief

This page is one person within Rapport Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Rapport Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Bradley Galer's compensation dossier · One-time report. No refunds.